Document Detail

Treatment of immature baboons for 28 days with early nasal continuous positive airway pressure.
MedLine Citation:
PMID:  14962819     Owner:  NLM     Status:  MEDLINE    
Using the 125-day baboon model of long-term bronchopulmonary dysplasia, we hypothesized that early use of nasal continuous positive airway pressure (nCPAP), a noninvasive ventilatory method, combined with prophylactic surfactant therapy would permit continuation of alveolar and vascular development in the lung. Retrospective human studies have shown that infants treated with nCPAP spend less time on mechanical ventilation and thereby sustain less volutrauma. After delivery by cesarean section at 125 days (term, 185 days), the infants received two doses of surfactant (Curosurf) and daily caffeine citrate. Weaning from low-volume positive pressure ventilation to nCPAP was attempted at 24 hours of age. Serial physiological parameters were recorded. Lung histopathology and morphometric measurements of nCPAP animals were done after necropsy at 28 days and data were compared with 125- and 156-day gestational controls. Documented episodes of clinical sepsis and pneumonia at postmortem examination were absent. nCPAP lungs showed enlarged thin-walled air spaces with minimal fibroproliferation and scattered secondary crests. Internal surface area and surface-to-volume ratio dimensions were similar to those of 156-day gestational control lungs, the intrauterine developmental control. nCPAP is an effective noninvasive ventilatory technique that minimizes lung injury in baboons at risk of developing bronchopulmonary dysplasia.
Merran A Thomson; Bradley A Yoder; Vicki T Winter; Helen Martin; Deborah Catland; Theresa M Siler-Khodr; Jacqueline J Coalson
Related Documents :
17641159 - Brief, large tidal volume ventilation initiates lung injury and a systemic response in ...
7626919 - Effects of lung surfactant factor (lsf) treatment on gas exchange and histopathological...
9504789 - Cardiopulmonary interaction during partial liquid ventilation in surfactant-treated pre...
7842219 - Pulmonary surfactant maintains patency of conducting airways in the rat.
9890919 - Neutral lipids induce critical behavior in interfacial monolayers of pulmonary surfactant.
8354209 - Evaluation of local endobronchial antigen challenges in the investigation of equine chr...
1903819 - The interaction of vasodilating drugs and sympathetic blockade in normal and ischemic c...
9800829 - The superiority of pinacidil over adenosine cardioplegia in blood-perfused isolated hea...
3052159 - The antigravity suit in neurosurgery. cardiovascular responses in seated neurosurgical ...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.     Date:  2004-02-12
Journal Detail:
Title:  American journal of respiratory and critical care medicine     Volume:  169     ISSN:  1073-449X     ISO Abbreviation:  Am. J. Respir. Crit. Care Med.     Publication Date:  2004 May 
Date Detail:
Created Date:  2004-04-26     Completed Date:  2004-05-13     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  9421642     Medline TA:  Am J Respir Crit Care Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1054-62     Citation Subset:  AIM; IM    
Division of Paedatrics, Hammersmith Hospital, London, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Factors
Animals, Newborn
Biological Agents / therapeutic use
Bronchoalveolar Lavage Fluid / chemistry
Bronchopulmonary Dysplasia / etiology,  pathology,  therapy*
Caffeine / therapeutic use
Cesarean Section
Citrates / therapeutic use
Combined Modality Therapy
Continuous Positive Airway Pressure / instrumentation,  methods*
Disease Models, Animal*
Drug Combinations
Feasibility Studies
Infant, Newborn
Intensive Care, Neonatal / methods
Lung / growth & development
Parenteral Nutrition, Total / methods
Phospholipids / therapeutic use
Pulmonary Gas Exchange
Risk Factors
Time Factors
Ventilator Weaning / methods
Grant Support
Reg. No./Substance:
0/Biological Agents; 0/Citrates; 0/Drug Combinations; 0/Phospholipids; 58-08-2/Caffeine; 69-22-7/caffeine citrate; KE3U2023NP/poractant alfa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Functional polymorphisms in the promoter region of macrophage migration inhibitory factor and atopy.
Next Document:  Particulate matter exposure in cars is associated with cardiovascular effects in healthy young men.